MedTrace Logo

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

NCT05966688 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2024-03-04

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the pharmacokinetics (PK) of SPR720, azithromycin, and ethambutol, administered separately and co-administered, in healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

SPR720

Multiple oral doses of SPR720 capsules.

DRUG

Azithromycin

Multiple oral doses of azithromycin.

DRUG

Ethambutol

Multiple oral doses of ethambutol.

Sponsors & Collaborators

  • Spero Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-04
Primary Completion
2024-01-30
Completion
2024-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05966688 on ClinicalTrials.gov